Bio‑Techne (TECH) 8‑K: 90.45% quorum; 9 directors elected

Bio‑Techne Corporation filed an 8‑K reporting that it issued a press release describing results of operations for the quarter ended September 30, 2025 and its financial condition as of that date.

Rhea-AI Filing Summary

Bio‑Techne Corporation filed an 8‑K reporting that it issued a press release describing results of operations for the quarter ended September 30, 2025 and its financial condition as of that date. The company also announced via a separate press release that its Board declared a cash dividend.

Shareholders held the Annual Meeting with a quorum of 140,827,559 shares, representing approximately 90.45% of outstanding shares. Shareholders set the number of directors at nine (For 140,278,598; Against 314,005; Abstain 234,956), and elected all nine nominees by a majority standard. The advisory vote on executive compensation passed (For 100,792,824; Against 39,025,321; Abstain 1,009,414). Shareholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026 (For 137,578,559; Against 3,055,503; Abstain 193,497).

8-K Event Classification

4 items: 2.02, 5.07, 8.01, 9.01

4 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Bio‑Techne (TECH) disclose in its latest 8‑K?

The company furnished a press release on quarterly results for the quarter ended September 30, 2025, reported Annual Meeting voting outcomes, and announced a cash dividend via press release.

How many Bio‑Techne shares were represented at the Annual Meeting?

A quorum of 140,827,559 shares was present, representing approximately 90.45% of outstanding shares.

Were Bio‑Techne’s director nominees elected?

Yes. Shareholders set the board at nine directors and elected all nine nominees by a majority standard.

What were the results of Bio‑Techne’s say‑on‑pay vote?

The advisory vote on executive compensation passed: For 100,792,824; Against 39,025,321; Abstain 1,009,414.

Who is Bio‑Techne’s auditor for fiscal year ending June 30, 2026?

Shareholders ratified KPMG LLP (For 137,578,559; Against 3,055,503; Abstain 193,497).

Did Bio‑Techne announce a dividend?

Yes. The company announced a cash dividend in a press release attached as an exhibit.

What period did the reported results cover for Bio‑Techne (TECH)?

The results relate to the quarter ended September 30, 2025 and financial condition as of that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/05/2025 - 06:31 AM Learn about SEC filing dates

0000842023false00008420232025-10-302025-10-30

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): October 30, 2025

BIO-TECHNE CORPORATION

(Exact Name of Registrant as Specified in its Charter)

​

Minnesota	0-17272	41-1427402
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

​

​

 55413

​

614 McKinley Place NE

Minneapolis, Minnesota 55413

(Address of Principal Executive Offices) (Zip Code)

(612) 379-8854

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TECH	NASDAQ

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

​

☐ Emerging growth company

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 2.02 Results of Operations and Financial Condition

​

A copy of the press release issued by Bio-Techne Corporation (the “Company”) on November 5, 2025, describing the results of operations for the quarter ended September 30, 2025 and its financial condition as of September 30, 2025 is attached hereto as Exhibit 99.1.

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

​

​

Item 5.07 Submission of Matters to a Vote of Security Holders

​

A quorum was present at the Annual Meeting with 140,827,559 shares represented personally or by proxy, which represents approximately 90.45% of the outstanding shares of the Company's common stock. The voting results at the Annual Meeting were as set forth below.

​

Proposal No. 1 – The shareholders voted to set the number of directors at nine:    

​

			​
For	Against	Abstain	Broker Non-Vote
140,278,598	314,005	234,956	0

​

Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors:

​
​	For	Against	Abstain	Broker Non-Vote
Robert V. Baumgartner	134,015,677	6,570,465	241,417	0
Julie L. Bushman	136,076,243	4,511,497	239,819	0
John L. Higgins	135,131,210	5,460,347	236,002	0
Kim Kelderman	139,472,895	1,087,500	267,164	0
Joseph D. Keegan	136,272,153	4,315,695	239,711	0
Alpna Seth	134,628,283	5,957,489	241,787	0
Rupert Vessey	137,441,139	3,145,646	240,774	0
Judith Klimovsky	138,104,299	2,120,409	602,851	0
Amy Herr	139,257,947	1,323,873	245,739	0

Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation.

​

Proposal No. 3 – The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement:

9,
For	Against	Abstain	Broker Non-Vote
100,792,824	39,025,321	1,009,414	0

​

Proposal No. 4 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026.

40			​
For	Against	Abstain	Broker Non-Vote
137,578,559	3,055,503	193,497	0

​

​

​

Item 8.01 Other Events

​

A copy of the press release issued by Bio-Techne Corporation on November 5, 2025, announcing a cash dividend is attached hereto as Exhibit 99.2.

​

Item 9.01 Financial Statements and Exhibits

​

(d) Exhibits
​	​
99.1	Press Release, dated November 5, 2025, announcing results of operations
99.2	Press Release, dated November 5, 2025, announcing cash dividend
​	​
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	BIO-TECHNE CORPORATION
​	​
Date: November 5, 2025	By:	/s/ Shane V. Bohnen
​	Shane V. Bohnen
​	Senior Vice President, General Counsel and Secretary

​

​

​

​

​